FLCN is considered a tumor suppressor, following the Knudson “second hit” model, since somatic mutation or loss of heterozygosity of the non-affected allele has been observed in BHD-associated renal tumors and in animal models (Schmidt and Linehan, 2018). Here, FLCN is linked to neoplasm.